You’re just a few questions away from results.
Taxotere has been linked to Permanent or Persistent Hair Loss despite label claiming hair “generally grows back”
Taxotere (docetaxel) is a cancer medication that interferes with the growth and spread of cancer cells in the body. Taxotere is used to treat breast cancer, lung cancer, prostate cancer, stomach cancer, and head/neck cancer. It was approved by the FDA on May 14, 1996.
Taxotere is administered through intravenously. A recent study published in 2012 stated that “severe and permanent female hair loss, especially scalp alopecia, is a new and rare cutaneous side-effect of the sequential FEC–docetaxel regimen used for early breast cancer adjuvant treatment”.
Europe and Canada have displayed warnings of permanent hair loss as early as 2005 in Europe and 2012 in Canada. Taxotere has yet to display this same warning in the United States.
Women who were administered Taxotere were told that their hair loss would only be temporary when, in fact, it is a permanent side effect. The failure of the drug company, hospitals, and doctors to fully warn these women stripped them of their right to investigate alternative medications and forms of treatment. If the France based company, Sanofi Aventis, had honestly described the side effects of Taxotere, most women would probably have elected to use the American-made product, Taxol, that is just as effective without the permanent hair loss.